iTAbTM Pipeline      A-319      A-337
We have developed a product pipeline in different stage of pre-clinical and clinical development. In the hematopoietic cancers, we mainly focused on treating B cell malignancies including acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), and multiple myeloma (MM). In the non-hematopoietic cancers, iTAbs are intended to treat various cancers in liver and bile duct, lung, pancreas, stomach, and colon.

Copyright © 2021 ITabMed Co., Ltd. All Rights Reserved